India FY22 Earnings: Everyone’s Talking Of Big Spikes In Input, Logistics Costs
Executive Summary
The sharp escalation in prices of raw materials, solvents, excipients and logistics in a volatile operating environment charged by geopolitical tensions and supply chain challenges was one of the key talking points at the fiscal fourth quarter earnings discussions of leading Indian firms. With little hope for respite any time soon, companies are devising strategies to cope.
You may also be interested in...
Syngene COO On Delivering Cost Gains For mRNA Products
Syngene’s COO, Mahesh Bhalgat, tells Scrip the firm is better placed than some peers to serve clients for biologics-based advanced therapies and address the cost element for new modalities like mRNA. He also outlines the research, development and manufacturing services company's capabilities in oligonucleotide-based therapeutics, an area that's seeing growing interest.
Cipla Uncorks Peptide Injectables Pipeline
Cipla readies scale-up in peptide injectables with five filings in the US and gears for upcoming high-value launches for generic versions of Advair, Revlimid and Abraxane. The company is also exploring partnering opportunities for monkeypox.
Cipla Uncorks Peptide Injectables Pipeline, Eyes Partnering For Monkeypox
Cipla readies scale up in peptide injectables with five filings in the US and gears for upcoming high value launches for generic versions of Advair, Revlimid and Abraxane. The company is also exploring partnering opportunities for monkeypox.